Claims

1. A method of inhibiting fungal growth in a host comprising administering to a host infected with a fungi, a composition comprising an acceptable carrier and a compound selected from the group consisting of formulae 1a, 1b, 1c, 1d and 1e, for a time and under conditions effective to inhibit fungal growth wherein the structures of said formulae are as follows:



1a, Dolastatin 10
(Dov-Val-Dil-Dap-Doe)



1b, Dov-Val-Dil-Dap-Phe-3-[(5-phenyl)-1,4-thiadiazolamide]



1c, Dov-Val-Dil-Dap-Phe-3-[(5-thiomethyl)-1,4-thiadiazolamide]



1d, Dov-Val-Dil-Dap-Phe-OMe

1e, Dov-Val-Dil-Dap-Met-3-quinolylamide

2. The method according to claim 1 in which said fungal growth is *Cryptococcus neoformans*.

3. The method according to claim 1 in which said fungal growth are cryptococcosis and epidermal and systemic infections resulting from contact with *Cryptococcus neoformans*.

4. The method according to claim 9 in which said active ingredient is administered to said host by parenteral means.

5. The method according to claim 9 in which said active ingredient is administered topically to said host.

6. The method according to claim 9 in which said active ingredient is administered intravenously to said host.

7. The method according to claim 9 in which said active ingredient is administered in a suppository inserted in said host.

C 2

8. The method according to claim 5 wherein said carrier said carrier is selected from the group consisting of a water-and-oil emulsion, petrolatum, mineral oil, a moisturizer, and a solubilizer.

9. The method according to claim 3 wherein said host is a mammal.

10. The method according to claim 9 in which said mammal is a human.

11. The method according to claim 10 in which said active ingredient is administered to said host by parenteral means.

12. The method according to claim 10 in which said active ingredient is administered topically to said host.

13. The method according to claim 10 in which said active ingredient is administered intravenously to said host.

14. The method according to claim 10 in which said active ingredient is administered in a suppository inserted in said host.

15. The method according to claim 12 wherein said carrier said carrier is selected from the group consisting of a water-and-oil emulsion, petrolatum, mineral oil, a moisturizer, and a solubilizer.

16. A method of inhibiting growth of a fungus in a host that is infected with a fungus comprising administering to said host a composition comprising an acceptable carrier, and a compound selected from the group consisting of formulae 1a, 1b, 1c, 1d, and 1e, wherein said method, said composition is administered to the host for a time and under conditions effective to inhibit said fungal growth; and wherein the structures of said formulae are as follows:



1a, Dolastatin 10
(Dov-Val-Dil-Dap-Doe)



1b, Dov-Val-Dil-Dap-Phe-3-[(5-phenyl)-1,4-thiadiazolamide]